GR3005284T3 - - Google Patents

Info

Publication number
GR3005284T3
GR3005284T3 GR920401614T GR920401614T GR3005284T3 GR 3005284 T3 GR3005284 T3 GR 3005284T3 GR 920401614 T GR920401614 T GR 920401614T GR 920401614 T GR920401614 T GR 920401614T GR 3005284 T3 GR3005284 T3 GR 3005284T3
Authority
GR
Greece
Prior art keywords
alpha
double bond
androsten
aza
steroid
Prior art date
Application number
GR920401614T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3005284T3 publication Critical patent/GR3005284T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
GR920401614T 1987-01-28 1992-07-29 GR3005284T3 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/007,539 US4888336A (en) 1987-01-28 1987-01-28 Steroid 5-alpha-reductase inhibitors

Publications (1)

Publication Number Publication Date
GR3005284T3 true GR3005284T3 (OSRAM) 1993-05-24

Family

ID=21726780

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920401614T GR3005284T3 (OSRAM) 1987-01-28 1992-07-29

Country Status (13)

Country Link
US (1) US4888336A (OSRAM)
EP (1) EP0277002B1 (OSRAM)
JP (1) JPS63192800A (OSRAM)
AT (1) ATE77388T1 (OSRAM)
AU (1) AU608560B2 (OSRAM)
CA (1) CA1325006C (OSRAM)
DE (1) DE3871965T2 (OSRAM)
DK (4) DK168525B1 (OSRAM)
ES (1) ES2042725T3 (OSRAM)
GR (1) GR3005284T3 (OSRAM)
IE (1) IE61594B1 (OSRAM)
PT (1) PT86652B (OSRAM)
ZA (1) ZA88549B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US4814324A (en) * 1987-03-06 1989-03-21 Merck & Co., Inc. Sterol inhibitors of testosterone 5α-reductase
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5405978A (en) * 1989-05-30 1995-04-11 The Upjohn Company Oxidative preparation of 3,5-secoandrost-5-one-3,17 β-dioic acid
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
ES2189784T3 (es) * 1989-07-07 2003-07-16 Endorech Inc Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos.
AU643445B2 (en) * 1989-07-07 1993-11-18 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5250539A (en) * 1991-08-21 1993-10-05 Eli Lilly And Company Hexahydrobenzo[f]quinolinones
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) * 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones
DE69225244T2 (de) * 1991-12-20 1998-09-24 Glaxo Wellcome Inc Inhibitoren von testosteron-5-alpha reductase.
JPH07508034A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド １７−アミノ置換４−アザステロイド５α−レダクターゼ阻害剤
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
EP0641204B1 (en) * 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
WO1993023051A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
EP0646007B1 (en) * 1992-05-20 1997-08-13 Merck & Co. Inc. NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS
EP0641208B1 (en) * 1992-05-20 2000-08-02 Merck & Co. Inc. 4-azasteroid 5-alpha-reductase inhibitors
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
CA2135173A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel Ester derivatives of 4-aza-steroids
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
CZ286894A3 (en) * 1992-05-21 1995-09-13 Endorecherche Inc Pharmaceutical preparation
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
AU680818B2 (en) * 1992-05-21 1997-08-14 Endorecherche Inc. Improved antiandrogens
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
AU6413594A (en) * 1993-03-24 1994-10-11 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
DE69405760T2 (de) * 1993-06-28 1998-04-09 Merck & Co Inc 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
DE69942578D1 (de) 1998-05-22 2010-08-26 Univ R Bifunktionelle moleküle sowie darauf basierende therapien.
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
CN102316902B (zh) 2009-02-20 2014-09-24 to-BBB控股股份有限公司 基于谷胱甘肽的药物递送系统
IL295075A (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897202A (en) * 1956-03-19 1959-07-28 Monsanto Chemicals 3-keto-4-aza-delta5-steroids and method of preparing same
ZA791752B (en) * 1978-04-13 1980-11-26 Merck & Co Inc 4-aza-17 beta -substituted-5 alpha -androstan-3-ones useful as 5 alpha -reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors

Also Published As

Publication number Publication date
DK37388D0 (da) 1988-01-26
DE3871965T2 (de) 1993-01-14
AU608560B2 (en) 1991-04-11
ATE77388T1 (de) 1992-07-15
DK37388A (da) 1988-07-29
US4888336A (en) 1989-12-19
CA1325006C (en) 1993-12-07
PT86652B (pt) 1992-02-28
ES2042725T3 (es) 1993-12-16
DK169438B1 (da) 1994-10-31
DK168525B1 (da) 1994-04-11
EP0277002A3 (en) 1988-10-26
IE880189L (en) 1988-07-28
EP0277002B1 (en) 1992-06-17
DK73594A (da) 1994-06-21
DE3871965D1 (de) 1992-07-23
EP0277002A2 (en) 1988-08-03
DK169840B1 (da) 1995-03-13
ZA88549B (en) 1988-07-27
AU1077888A (en) 1988-08-04
DK196691D0 (da) 1991-12-05
JPS63192800A (ja) 1988-08-10
IE61594B1 (en) 1994-11-16
PT86652A (pt) 1988-02-01
DK196691A (da) 1991-12-05

Similar Documents

Publication Publication Date Title
GR3005284T3 (OSRAM)
GEP19981274B (en) Urinary follicle stimulating hormone, pharmaceutical composition, component of pharmaceutical composition
AU4703989A (en) Phosphinic acid substituted steroids as inhibitors of 5 alpha-reductase
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
IL72928A (en) Bronchodilating pharmaceutical compositions containing 5,6-dialkoxybenzothiophene-2-carboxylic acid
AU6857887A (en) Therapeutic agent
EP0293751A3 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
AU2726088A (en) Ampule for controlled administration of beneficial agent
IL80900A (en) Pharmaceutical composition containing fibrinolytic compounds and carbacyclin analogues for treatment of thrombosis
NZ239022A (en) Piperidyl ethers and thioethers; preparatory processes and pharmaceutical compositions
AU2159888A (en) Novel calcium supplements
ZA899670B (en) Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
AU1866888A (en) Pharmaceutical dosage unit containing 17beta-oestradiol and desogestrel
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
ZA878249B (en) Method and therapeutic compositions for the treatment of bleeding disorders
ZA87332B (en) Compositions containing fixed combinations
EP0256805A3 (en) Pharmaceutical compositions for the treatment of occlusive vascular diseases
PT83984A (en) Process for the preparation of novel 16,17-acetalsubstituted pregnane 21-oic derivatives and of pharmaceutical compositions containing the same
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
IL87320A (en) Polyhydro derivatives of 10,11-dihydro-5h-dibenzo-(a,d)cyclohepten-5,10-imine and pharmaceutical compositions containing them
IL94417A0 (en) Pharmaceutical compositions containing gestodene and methods for the preparation and use thereof
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
IL86731A (en) Pharmaceutical compositions containing estradien-3-one derivatives and androst-2-ene-carbonitrile derivatives
AU645042B2 (en) Use of a polypeptide having the activity of gamma interferon for the preparation of pharmaceutical compositions intended for the treatment of primary cancers of the pleura